ERBB2 and cancer: With respect to HER2+ and TNBC, the clinical utility of NAC has become embedded into best-practice guidelines: A recent update from ASCO recommends the use of NAC and trastuzumab for HER2+ cancers (with the exception of T1a-T1b N0 disease), with anthracycline and taxane-based chemotherapy and trastuzumab to be utilised in high-risk LN- cases and those with LN positivity [63].